ACLARIS THERAPEUTICS INC. - COMMON STOCK

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 мар 2025 07:00:05 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 фев 2025 06:59:55 Источник Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 фев 2025 06:50:01 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 янв 2025 16:01:21 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 янв 2025 16:30:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 дек 2024 16:30:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 ноя 2024 16:30:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 ноя 2024 09:45:01 Источник NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 ноя 2024 09:52:02 Источник NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 ноя 2024 08:10:41 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 ноя 2024 08:10:04 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

13 ноя 2024 09:53:10 Источник NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

11 ноя 2024 09:48:00 Источник NetDania Notify

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

06 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

17 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

10 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

07 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

16 июл 2024 16:01:43 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

06 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

07 май 2024 16:01:00 Источник Nasdaq GlobeNewswire